Agreement for joint research between LyseNTech and Zoonotic Infectious Disease Research Institute of Chonbuk National University

May 24, 2024

LyseNTech (CEO Myung Heejoon), a company specializing in bacteriophages, announced on May 22 that it had signed an agreement for joint research with the Chonbuk National University Zoonotic Infectious Disease Research Institute (Director Kim Jong Hoon). In order to solve the problem of antibiotic resistance, which is becoming more serious recently, measures to reduce antibiotic use based on the One Health concept are needed, and the important axis of this is humans and animals. Minsoo Kim, head of the research center at LyseNTech, which is developing bacteriophages and endolysins as new antibiotics, said that in responding to antibiotic resistance under this One Health concept, a more systematic development of new antibiotics is conducted through joint research with the institution specializing in zoonotic infectious diseases. In addition, it was announced that the development of new drugs could be accelerated by using animal facilities of biosafety level 2 and 3 (BSL 2, 3) owned by the Zoonotic Infectious Disease Research Institute. Meanwhile, LyseNTech received approval from the Ministry of Food and Drug Safety for phase 1 clinical trials for LNT103, a new endolysin pipeline targeting Gram-negative bacteria, in April.